Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 2Hereditary Sensory and Autonomic Neuropathies 2Stomach Neoplasms 1Recurrence 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Head and Neck Neoplasms 1HER2-positive Metastatic Breast Cancer 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma 1

Interventions

Cisplatin 7pembrolizumab 4Radiotherapy 3Paclitaxel 3fludarabine 2durvalumab 2aldesleukin 2Taxes 2Fluorouracil 2Cyclophosphamide 2Biopsy 2veliparib 1tremelimumab 1prednylidene 1niraparib 1fludarabine phosphate 1exifone 1entinostat 1dostarlimab 1deltacortene 1dehydroftorafur 1bintrafusp alfa protein, human 1advexin 1Tomography, X-Ray Computed 1Specimen Handling 1Radiosurgery 1Radiation 1Prednisone 1Platinum 1Pemetrexed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Oropharyngeal Neoplasms × Alpelisib × Clear all
NCT02298595 2017-11-13

Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

University of Pittsburgh

Phase 1/2 Withdrawn
Head & Neck

Carcinoma, Carcinoma, Squamous Cell, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡